Pharmacokinetics and safety following a single oral dose of niraparib in patients with moderate hepatic impairment.

被引：0
|
作者：
Akce, Mehmet
El-Khoueiry, Anthony B.
Piha-Paul, Sarina Anne
Bacque, Emeline
Pan, Peng
Zhang, Zhi-Yi
Ewesuedo, Reginald
Gupta, Divya
Milton, Ashley
Judson, Patricia
O'Bryant, Cindy L.
机构：
[1] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA
[2] Univ Southern Calif, Norris Comprehens Canc Ctr, Newport Beach, CA USA
[3] Univ Southern Calif, Hoag Mem Hosp, Presbyterian Canc Ctr, Newport Beach, CA USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Program 1, Houston, TX 77030 USA
[5] GlaxoSmithKline, Waltham, MA USA
[6] Univ Colorado, Canc Ctr, Aurora, CO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6054
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Pharmacokinetics and tolerability of doxorubicin in newly diagnosed lymphoma patients with hepatic impairment.
    Lai, Catherine
    Cole, Diane
    Shovlin, Margaret
    Widemann, Brigitte C.
    Dunleavy, Kieron
    Wilson, Wyndham Hopkins
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [42] The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment
    Jin, Feng
    Robeson, Michelle
    Zhou, Huafeng
    Hisoire, Grace
    Ramanathan, Srini
    JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 55 (08): : 944 - 952
  • [43] Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics and Safety of Carisbamate
    Moore, Kenneth
    Zannikos, Peter
    Solanki, Bhavna
    Greenspan, Andrew
    Verhaeghe, Tom
    Brashear, H. Robert
    JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 52 (05): : 738 - 746
  • [44] PHARMACOKINETICS AND SAFETY OF SINGLE-DOSE BEPIROVERSIN IN ADULTS WITH MODERATE HEPATIC IMPAIRMENT AND HEALTHY MATCHED CONTROLS (B-ASSURED)
    Han, K.
    Noormohamed, N.
    Lukic, T.
    Marbury, T.
    Lawitz, E.
    Prescott, H.
    Magee, M.
    Nader, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S17 - S17
  • [45] Pharmacokinetics, safety, and tolerability of the oral renin inhibitor aliskiren in patients with hepatic impairment
    Vaidyanathan, Sujato
    Warren, Vance
    Yeh, ChingMing
    Bizot, Marie-Noelle
    Dieterich, Hans Armin
    Dole, William R.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (02): : 192 - 200
  • [46] Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment
    Rolfo, Christian
    Isambert, Nicolas
    Italiano, Antoine
    Molife, L. Rhoda
    Schellens, Jan Hm
    Blay, Jean-Yves
    Decaens, Thomas
    Kristeleit, Rebecca
    Rosmorduc, Olivier
    Demlova, Regina
    Lee, Myung-Ah
    Ravaud, Alain
    Kopeckova, Katerina
    Learoyd, Maria
    Bannister, Wendy
    Locker, Gershon
    de Vos-Geelen, Judith
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (09) : 1807 - 1818
  • [47] Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment
    Almeida, Luis
    Potgieter, J. Hendrick
    Maia, Joana
    Potgieter, M. Alida
    Mota, Fernando
    Soares-da-Silva, P.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 64 (03) : 267 - 273
  • [48] Pharmacokinetics of Rolapitant in Patients With Mild to Moderate Hepatic Impairment
    Wang, Jing
    Wang, Xiaodong
    Zhang, Zhi-Yi
    Arora, Sujata
    Lu, Sharon
    Kansra, Vikram
    JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (05): : 686 - 693
  • [49] Pharmacokinetics and Safety Evaluation of Single-Dose Saroglitazar Magnesium in Subjects with Hepatic Impairment
    Lawitz, Eric
    Parmar, Deven
    Momin, Taufik
    Shaikh, Farheen
    Patel, Harilal
    Hayes, Helen
    Swint, Kimberly
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2023, 12 (12): : 1142 - 1155
  • [50] Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment
    Luis Almeida
    J. Hendrick Potgieter
    Joana Maia
    M. Alida Potgieter
    Fernando Mota
    P. Soares-da-Silva
    European Journal of Clinical Pharmacology, 2008, 64 : 267 - 273
12345